The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neuronal Synuclein Disease Endotypes 2024, 2025Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Study Rationale: Progressive aggregation of alpha-synuclein and the subsequent loss of affected brain cells starts 10 to 20 years before the onset of Parkinson’s disease (PD) symptoms. Early diagnosis...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Investigating the Early Events in Parkinson’s Disease Pathobiology through Longitudinal Evaluation of Asymptomatic Carriers of Alpha-synuclein Mutations
Study Rationale: Essentially nothing is known about the sequence of biological and physiological events that ultimately lead to the clinical manifestations of Parkinson’s disease (PD). The existence...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Characterization of a Preclinical Model Bearing a Parkinson’s Disease–linked Mutation in PLA2G6
Study Rationale: Mutations in the PLA2G6 gene lead to neurodegeneration linked to Parkinson’s disease (PD), but the mechanism is unknown. The gene encodes an enzyme that breaks down the lipid...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Targeting Mitochondrial Complex I in Parkinson’s Disease
Study Rationale: Three of the primary risk factors for Parkinson's disease (PD)—aging, environmental toxins and genetic mutations—all lead to impaired function of mitochondria, structures that...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Evaluating the Role of CK1d Inhibition in Sleep Dysregulation and Alpha-synuclein Pathology in Preclinical Models of Parkinson’s Disease
Study Rationale: Disrupted sleep is an early sign of Parkinson’s disease (PD) that worsens as the disease progresses. Chronic symptoms of PD include alternations in sleep patterns and changes in the...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Brain-specific LRRK Inhibitors for Parkinson’s Disease
Study Rationale: Mutations in LRRK2 are thought to be causative for Parkinson’s disease (PD), but increases in LRRK2 activity have also been observed in non-familial cases of PD. As a result, LRRK2...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.